Cargando…
Molecular Neuroimaging of the Dopamine Transporter as a Patient Enrichment Biomarker for Clinical Trials for Early Parkinson's Disease
The Critical Path for Parkinson's (CPP) Imaging Biomarker and Modeling and Simulation working groups aimed to achieve qualification opinion by the European Medicines Agency (EMA) Committee for Medical Products for Human Use (CHMP) for the use of baseline dopamine transporter neuroimaging for pa...
Autores principales: | Romero, Klaus, Conrado, Daniela, Burton, Jackson, Nicholas, Timothy, Sinha, Vikram, Macha, Sreeraj, Ahamadi, Malidi, Cedarbaum, Jesse, Seibyl, John, Marek, Kenneth, Basseches, Peter, Hill, Derek, Somer, Ed, Gallagher, Jill, Dexter, David T., Roach, Arthur, Stephenson, Diane |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510371/ https://www.ncbi.nlm.nih.gov/pubmed/30706986 http://dx.doi.org/10.1111/cts.12619 |
Ejemplares similares
-
The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease
por: Stephenson, Diane, et al.
Publicado: (2019) -
Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis
por: Conrado, Daniela J., et al.
Publicado: (2017) -
Performance of longitudinal item response theory models in shortened or partial assessments
por: Arrington, Leticia, et al.
Publicado: (2020) -
Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson’s disease trial
por: Hutchison, R. Matthew, et al.
Publicado: (2021) -
Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T‐VEC) a first‐in‐class oncolytic viral therapy in patients with advanced melanoma
por: Ahamadi, Malidi, et al.
Publicado: (2023)